Aldeyra Therapeutics, Inc. (ALDX) shareholders
Close on Nov 17, 2026Market cap $41.86MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Perceptive Life Sciences Master Fund, Ltd. Joint filing with Perceptive Advisors LLC (8.70%), Joseph Edelman (8.70%) | 5,222,311 | 8.70% | 13G (passive) amendment | Sep 30, 2025 |
| Perceptive Advisors LLC Joint filing with Joseph Edelman (7.00%), Perceptive Life Sciences Master Fund, Ltd. (7.00%) | 4,185,632 | 7.00% | 13G (passive) amendment | Dec 31, 2025 |
| AQR Capital Management, LLC Joint filing with AQR Capital Management Holdings, LLC (6.22%) | 3,751,558 | 6.22% | 13G (passive) | Jun 30, 2026 |
| Barclays PLC | 3,310,587 | 5.48% | 13G (passive) | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ALDX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Knoll Capital Management, LLC | 5,475,516 | 9.08% | $11.66M | – | 6.50% |
| Aqr Capital Management LLC | 3,751,558 | 6.22% | $7.99M | +921,683 | 0.00% |
| Kingdon Capital Management, L.L.C. | 2,652,315 | 4.40% | $5.65M | +500,000 | 0.58% |
| Vanguard Capital Management LLC | 2,361,796 | 3.92% | $5.03M | −1,946 | 0.00% |
| D. E. Shaw & Co., Inc. | 1,940,338 | 3.22% | $4.13M | +536,348 | 0.00% |
| Marshall Wace, Llp | 1,506,974 | 2.50% | $3.21M | +1,377,281 | 0.00% |
| 683 Capital Management, LLC | 1,450,000 | 2.40% | $3.09M | −50,000 | 0.15% |
| Jane Street Group, LLC | 1,375,115 | 2.28% | $2.93M | +406,224 | 0.00% |
| BlackRock, Inc. | 1,257,243 | 2.08% | $2.68M | −2,506,644 | 0.00% |
| Qube Research & Technologies Ltd | 1,128,803 | 1.87% | $2.40M | +1,041,725 | 0.00% |
| Acadian Asset Management LLC | 1,063,793 | 1.76% | $2.26M | +205,505 | 0.00% |
| Ardsley Advisory Partners LP | 975,000 | 1.62% | $2.08M | +25,000 | 0.22% |
| Renaissance Technologies LLC | 882,000 | 1.46% | $1.88M | +18,813 | 0.00% |
| Vanguard Portfolio Management LLC | 794,863 | 1.32% | $1.69M | −12,915 | 0.00% |
| Goldman Sachs Group Inc | 725,444 | 1.20% | $1.55M | +182,298 | 0.00% |
| Jacobs Levy Equity Management, Inc | 646,840 | 1.07% | $1.38M | −149,976 | 0.00% |
| Morgan Stanley | 608,321 | 1.01% | $1.30M | +89,679 | 0.00% |
| Geode Capital Management, LLC | 596,029 | 0.99% | $1.27M | −655,623 | 0.00% |
| Dimensional Fund Advisors LP | 529,083 | 0.88% | $1.13M | −95,087 | 0.00% |
| Gsa Capital Partners Llp | 472,564 | 0.78% | $1.01M | +225,370 | 0.06% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 108 | 37M | 60.9% | 19 / 31 | 44 / 37 | 8M | 9M |
| Q1 2026 | 128 | 37M | 61.9% | 24 / 50 | 37 / 29 | 11M | 9M |
| Q4 2025 | 136 | 39M | 64.6% | 20 / 38 | 54 / 11 | 3M | 4M |
| Q3 2025 | 131 | 39M | 64.9% | 24 / 57 | 25 / 15 | 7M | 2M |
| Q2 2025 | 122 | 34M | 56.8% | 20 / 46 | 33 / 24 | 6M | 9M |
| Q1 2025 | 126 | 38M | 62.8% | 24 / 27 | 46 / 14 | 4M | 3M |
| Q4 2024 | 119 | 37M | 61.8% | 25 / 38 | 25 / 16 | 4M | 3M |
| Q3 2024 | 112 | 37M | 60.9% | 19 / 40 | 24 / 8 | 7M | 2M |
| Q2 2024 | 103 | 35M | 58.6% | 18 / 34 | 32 / 16 | 3M | 4M |
| Q1 2024 | 101 | 36M | 59.9% | 14 / 32 | 32 / 18 | 2M | 2M |
| Q4 2023 | 105 | 36M | 59.0% | 21 / 25 | 46 / 36 | 7M | 9M |
| Q3 2023 | 120 | 38M | 62.6% | 15 / 41 | 37 / 14 | 2M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
109 funds held ALDX in Q1 2026, 66% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ALDX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,784,433 | 2.96% | $3.80M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 521,515 | 0.86% | $1.11M | 0.00% | Jun 30, 2026 |
| Vanguard Explorer Fund | 331,506 | 0.55% | $510.52K | 0.00% | Jul 31, 2026 |
| Small Company Growth Portfolio | 308,146 | 0.51% | $656.35K | 0.04% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 276,801 | 0.46% | $484.40K | 0.00% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 262,161 | 0.43% | $458.78K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 187,530 | 0.31% | $399.44K | 0.03% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 154,611 | 0.26% | $270.57K | 0.00% | May 31, 2026 |
| U.S. Micro Cap Portfolio | 140,334 | 0.23% | $216.11K | 0.00% | Jul 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 105,149 | 0.17% | $161.93K | 0.01% | Jul 31, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 93,498 | 0.15% | $199.15K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 85,509 | 0.14% | $149.64K | 0.00% | May 31, 2026 |
| Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF | 74,423 | 0.12% | $130.24K | 0.01% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 72,731 | 0.12% | $127.28K | 0.00% | May 31, 2026 |
| PACE Small/Medium Co Growth Equity Investments | 52,300 | 0.09% | $80.54K | 0.03% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Todd C. Brady | President and CEO, Director | 1,721,298 | 2.85% | Jun 5, 2026 |
| Michael Alfieri | Principal Financial Officer | 17,500 | 0.03% | Nov 13, 2026 |
| Stephen Machatha | Chief Development Officer | 222,010 | 0.37% | Aug 13, 2025 |
| Darlene M. Deptula-Hicks | Director | 7,500 | 0.01% | Nov 16, 2026 |
| Richard Douglas | Director | 395,000 | 0.65% | Nov 13, 2026 |
| William D. Clark | Director | – | – | Jun 11, 2026 |
| Ben Bronstein | Director | 28,248 | 0.05% | Jun 11, 2026 |
| Gary M. Phillips | Director | 14,812 | 0.02% | Jun 11, 2026 |
| Neal Walker | Director | 15,854 | 0.03% | Jun 11, 2026 |
| Nancy Miller-Rich | Director | 922 | 0.00% | Jun 11, 2026 |
| Martin Joseph Joyce | Director | 23,967 | 0.04% | Jun 12, 2025 |
| Advisors Llc Perceptive | 10% owner | 11,350,085 | 18.81% | Apr 7, 2025 |
| Life Sciences Master Fund Ltd Perceptive | 10% owner | 5,875,851 | 9.74% | Apr 7, 2025 |
| Joseph Edelman | 10% owner | 9,275,851 | 15.38% | Apr 7, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Darlene M. Deptula-Hicks Director | Nov 12, 2026 | Buy | +7,500 | $0.65 | $4.88K | 7,500 |
| Michael Alfieri Principal Financial Officer | Nov 11, 2026 | Buy | +10,000 | $0.65 | $6.50K | 17,500 |
| Richard Douglas Director | Nov 11, 2026 | Buy | +200,000 | $0.64 | $128.90K | 395,000 |
| Todd C. Brady President and CEO, Director | Jun 3, 2026 | Buy | +250,000 | $1.67 | $417.50K | 1,721,298 |
| Richard Douglas Director | Mar 19, 2026 | Buy | +70,000 | $1.40 | $98.00K | 195,000 |
| Michael Alfieri Principal Financial Officer | Mar 18, 2026 | Buy | +5,000 | $1.42 | $7.10K | 7,500 |
| Michael Alfieri Principal Financial Officer | Aug 13, 2025 | Buy | +2,500 | $5.30 | $13.25K | 2,500 |
| Stephen Machatha Chief Development Officer | Aug 11, 2025 | Sale | −22,073 | $5.15 | $113.68K | 221,799 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Apr 3, 2025 | Sale | −3,400,000 | $1.42 | $4.83M | 5,875,851 |
| Stephen Machatha Chief Development Officer | Aug 12, 2024 | Sale | −16,041 | $4.74 | $76.03K | 236,771 |
| Bruce Greenberg See Remarks | Aug 12, 2024 | Sale | −10,834 | $4.74 | $51.35K | 126,382 |
| Joseph Edelman 10% owner | Apr 5, 2024 | Buy | +37,712 | $4.74 | $178.75K | 9,275,851 |
| Joseph Edelman 10% owner | Apr 4, 2024 | Buy | +140,281 | $4.67 | $655.11K | 9,238,139 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Apr 3, 2024 | Buy | +309,847 | $4.09 | $1.27M | 9,097,858 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Apr 2, 2024 | Buy | +186,051 | $3.44 | $640.02K | 8,788,011 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Apr 1, 2024 | Buy | +8,374 | $3.25 | $27.22K | 8,601,960 |
| Stephen Machatha Chief Development Officer | Mar 12, 2024 | Sale | −11,537 | $3.16 | $36.46K | 252,812 |
| Stephen Machatha Chief Development Officer | Mar 12, 2024 | Sale | −11,537 | $3.16 | $36.46K | 243,495 |
| Todd C. Brady President and CEO, Director | Mar 12, 2024 | Sale | −85,324 | $3.05 | $260.24K | 1,471,298 |
| Bruce Greenberg See Remarks | Mar 11, 2024 | Sale | −13,201 | $3.41 | $45.02K | 130,154 |
| Bruce Greenberg See Remarks | Mar 11, 2024 | Sale | −13,201 | $3.41 | $45.02K | 120,699 |
| Stephen Machatha Chief Development Officer | Mar 11, 2024 | Sale | −18,231 | $3.41 | $62.17K | 255,032 |
| Todd C. Brady President and CEO, Director | Mar 11, 2024 | Sale | −97,914 | $3.27 | $320.18K | 1,556,622 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Oct 18, 2023 | Sale | −306,499 | $1.74 | $533.31K | 8,593,586 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Oct 16, 2023 | Sale | −2,450,000 | $1.60 | $3.92M | 8,900,085 |
| Todd C. Brady President and CEO, Director | Sep 7, 2023 | Option exercise | +32,953 | $0.55 | $18.12K | 1,680,322 |
| Todd C. Brady President and CEO, Director | Sep 7, 2023 | Option exercise | +48,021 | $0.55 | $26.41K | 1,728,343 |
| Todd C. Brady President and CEO, Director | Sep 7, 2023 | Tax withholding | −73,807 | $7.22 | $532.89K | 1,654,536 |
| Todd C. Brady President and CEO, Director | Sep 7, 2023 | Option exercise | +192,084 | $0.55 | $105.65K | 1,647,369 |
| Gary M. Phillips Director | Sep 7, 2023 | Option exercise | +5,437 | $0.55 | $2.99K | 14,812 |
| Neal Walker Director | Aug 22, 2023 | Option exercise | +9,604 | $0.55 | $5.28K | 15,854 |
| Ben Bronstein Director | Jun 27, 2023 | Option exercise | +9,604 | $0.55 | $5.28K | 28,248 |
| Nancy Miller-Rich Director | Apr 12, 2023 | Buy | +509 | $10.13 | $5.16K | 922 |
| Todd C. Brady President and CEO, Director | Feb 28, 2023 | Award | +238,750 | – | – | 1,455,285 |
| Advisors Llc Perceptive 10% owner | Aug 10, 2022 | Buy | +15,000 | $7.85 | $117.75K | 11,350,085 |
| Advisors Llc Perceptive 10% owner | Aug 9, 2022 | Buy | +100,000 | $7.50 | $750.00K | 11,335,085 |
| Joseph Edelman 10% owner | Aug 8, 2022 | Buy | +97,000 | $7.24 | $702.28K | 11,235,085 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Aug 5, 2022 | Buy | +141,000 | $6.95 | $979.95K | 11,138,085 |
| Joseph Edelman 10% owner | Aug 4, 2022 | Buy | +95,100 | $6.17 | $586.77K | 10,997,085 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Aug 3, 2022 | Buy | +100,000 | $5.84 | $584.00K | 10,901,985 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Aug 2, 2022 | Buy | +412,406 | $5.59 | $2.31M | 10,801,985 |
| Advisors Llc Perceptive 10% owner | Aug 1, 2022 | Buy | +144,185 | $5.05 | $728.13K | 10,389,579 |
| Advisors Llc Perceptive 10% owner | Jul 29, 2022 | Buy | +222,123 | $5.03 | $1.12M | 10,245,394 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Jul 28, 2022 | Buy | +119,392 | $5.00 | $596.96K | 10,023,271 |
| Bruce Greenberg See Remarks | Jul 15, 2022 | Award | +126,087 | – | – | 133,900 |
| Stephen Machatha Chief Development Officer | Jul 15, 2022 | Award | +185,605 | – | – | 273,263 |
| Todd C. Brady President and CEO, Director | Jun 23, 2022 | Buy | +17,700 | $3.36 | $59.47K | 1,216,535 |
| Martin Joseph Joyce Director | Jun 23, 2022 | Buy | +4,323 | $3.48 | $15.04K | 23,967 |
| Joshua Reed Chief Financial Officer | Mar 30, 2022 | Award | +93,322 | – | – | 274,825 |
| Stephen Machatha Chief Development Officer | Mar 30, 2022 | Award | +64,395 | – | – | 87,658 |
| Todd C. Brady President and CEO, Director | Mar 30, 2022 | Award | +250,000 | – | – | 1,198,835 |
| Nancy Miller-Rich Director | May 3, 2021 | Buy | +413 | $12.81 | $5.29K | 413 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | May 3, 2021 | Buy | +1,200,000 | $12.50 | $15.00M | 9,903,879 |
| Todd C. Brady President and CEO, Director | Apr 12, 2021 | Award | +46,619 | – | – | 948,835 |
| Joseph Edelman 10% owner | Jan 19, 2021 | Buy | +1,368,421 | $9.50 | $13.00M | 8,703,879 |
| Advisors Llc Perceptive 10% owner | Jan 8, 2021 | Buy | +50,000 | $7.60 | $380.00K | 7,335,458 |
| Advisors Llc Perceptive 10% owner | Jan 8, 2021 | Buy | +152,668 | $10.21 | $1.56M | 7,285,458 |
| Advisors Llc Perceptive 10% owner | Jan 8, 2021 | Buy | +347,332 | $9.21 | $3.20M | 7,132,790 |
| Advisors Llc Perceptive 10% owner | Jan 7, 2021 | Buy | +500,000 | $8.13 | $4.07M | 6,785,458 |
| Advisors Llc Perceptive 10% owner | Jul 9, 2020 | Buy | +3,200,000 | $4.25 | $13.60M | 6,285,458 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Aldeyra Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 11,820 shares on Oct 9, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Stephen Machatha Officer | Aug 12, 2025 | 22,074 | $116.11K | Aug 12, 2025 | Restricted Stock Unit Grant |
| Bruce Greenberg Officer | Aug 12, 2024 | 10,834 | $55.25K | Aug 12, 2024 | Restricted Stock Unit Award |
| Stephen Machatha Officer | Aug 12, 2024 | 16,041 | $81.81K | Aug 12, 2024 | Restricted Stock Unit Award |
| Stephen Machatha Officer | Mar 12, 2024 | 11,537 | $36.50K | Mar 12, 2024 | Employee Stock Purchase Plan |
| Stephen Machatha Officer | Mar 11, 2024 | 18,231 | $66.00K | Mar 11, 2024 | Restricted Stock Unit Award |
| Bruce Greenberg Officer | Mar 11, 2024 | 13,201 | $47.79K | Mar 11, 2024 | Restricted Stock Unit Award |
| Todd C. Brady Officer | Mar 11, 2024 | 183,238 | $595.52K | Mar 11, 2024 | RETAIL PURCHASE |
See a number that looks wrong?